Source disclosure: February 09, 2026
Oncolys BioPharma Inc. [4588.T]
TOKYO, Feb 09 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) reported a lower net profit of ¥2.058 billion for the fiscal year ended December 2025, compared to a loss of ¥2.058 billion in the previous year.
Revenue decreased to ¥28 million from ¥31 million due to unfavorable exchange rates despite income from Transposon Inc. Research and development expenses fell to ¥61 million from ¥61 million, contributing to the wider lower operating profit of ¥342 million. Cash flow improved significantly, driven by increased funding through stock issuance options and higher prepaid receipts.
The company secured a ¥3.999 billion loan from Mizuho Bank, which will be repaid partly from anticipated revenue from its drug candidate OBP-301 scheduled for launch in February 2026. Looking ahead, Oncolys expects significant fluctuations in performance due to uncertainties surrounding OBP-301's pricing, sales timing, and additional milestones from partner companies. The firm plans to rely on operational revenues and bank loans in 2026 without immediate plans for further equity financing via MS warrants.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing